TheFly reported on May 7 that PODD saw its valuation outlook revised as Goldman Sachs reduced its price target to $237 from ...

Insulet delivered robust Q1 2026 results, with revenue up 34% to $762M and operating margins expanding to 17.5%. Read more on ...

Insulet’s first quarter was marked by robust revenue growth, driven by continued adoption of its Omnipod 5 insulin delivery ...

Personalized algorithms may quietly sabotage how people learn, nudging them into narrow tunnels of information even when they start with zero prior knowledge. In the study, participants using ...

This article was co-authored with Emma Myer, a student at Washington and Lee University who studies Cognitive/Behavioral Science and Strategic Communication. In today’s digital age, social media has ...

Insulet’s latest earnings call carried an upbeat tone, with management emphasizing powerful revenue growth, expanding margins, and a fast-advancing product pipeline. While executives acknowledged ...

Insulet reported revenue of $761.7 million for the first quarter of 2026, an increase of 33.9% over the prior year. Total Omnipod revenue was $758.4 million, up 36.9%.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its ...

Abstract: Evolutionary reinforcement learning (ERL), which integrates the evolutionary algorithms (EAs) and reinforcement learning (RL) for optimization, has demonstrated remarkable performance ...

Insulet (NASDAQ:PODD) reported what executives described as a “strong start” to fiscal 2026, posting double-digit revenue ...

Q1 2026 earnings call recap: raised revenue growth guidance, Omnipod 5 Libre 3 Plus integration, margins, risks & Q2 headwind—read now.

Insulet (Nasdaq:PODD) today reported first-quarter financial results that came in well ahead of the consensus forecast on ...